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Endotoxin (LPS), mterleukm-1jI (IL-l) and tumor necrosis factor-a (TNF) mcreased the expression of tissue factor. a membrane-anchored 
glycoprotein that initiates blood coagulation on the surface of cultured bovine aortic endothelial cells (ABAE) and human monocytes. These 
compounds simultaneously reduced the amount of thrombomodulin on the endothelial cell surface. further contributing to the procoagulant activity 
of the endothelium or monocytes. On endothelial cells and monocytes, mterleukin-4 (IL-4) and mterleukm-13 (IL-13). a newly described lympho- 
kine. both strongly inhibited LPS-induced tissue factor expression. a similar activity also being obtained with regard to the pyrogemc effects of 
IL-1 or TNF. When measured in parallel. IL-4 and IL-13 counteracted thrombomoduhn down-regulation induced by LPS. IL-1 or TNF m 
endothelial cells. These results therefore show that both IL-4 and IL-13 protect the endothehal and the monocyte surface agamst mflammatory 
mediator- induced procoagulant changes. 
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1. INTRODUCTION 
Tissue factor (TF) is an ubiquitous membrane-an- 
chored glycoprotein that initiates blood coagulation by 
forming a complex with circulating factors VII and VIIa 
[l]. Under normal circumstances, endothelial cells do 
not express TF activity while they constitutively express 
thrombomodulin (TM) which accelerates the thrombin- 
catalysed activation of protein C thus contributing to 
the anticoagulant properties of the endothelium. In 
some pathological situations, when the endothelium or 
the monocytes are exposed to inflammatory mediators, 
they can acquire procoagulant properties [24]. Indeed. 
stimulation of these cells by inflammatory compounds 
such as endotoxin, interleukin-lp (IL-lp) or tumor ne- 
crosis factor-a (TNF-cr) may alter the antithrombotic 
properties of the endothelium by inducing the expres- 
sion of TF and the down-regulation of TM, therefore 
promoting coagulation and thrombosis [24]. Only a 
few compounds have been shown to reduce the effect of 
these inflammatory mediators [5] and IL-4 has been 
recently described as an inhibitor of pyrogen-induced 
down-regulation of TM or TF expression in cultured 
vascular endothelial cells [6,7] and monocytes. 
This work was aimed at determining the inhibitory 
effect of IL-13, a newly-described lymphokine with IL- 
4-like properties [8] on the expression of TF and TM on 
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the surface of endothelial cells and monocytes induced 
by various inflammatory mediators. 
2. MATERIALS AND METHODS 
Adult bovine aortic endothelial cells (ABAE) (passage 7710) were 
isolated and cultured as already described [9] m 96-well microplates 
in Dulbecco’s modified Eagle medium, supplemented with 10% Fetal 
Calf Serum and bovine basic fibroblast growth factor (1 &ml) 
(Amersham, France). Mononuclear cells were obtained from human 
heparimzed blood as described by Boyum [IO]. Cells were plated for 
30 mm at 37°C into 96-well microplates (10’ ceils/well). Non-adherent 
cells were then removed and adherent monocyte (5 x 10” cells/well) 
were used for the assay. 
2.2. Determmatlon of time fuctor act&t! on the ceils 
Procoagulant activity was assayed according to Suprenant et al. 
[ll]. Briefly, adherent cells were Incubated for 18 h at 37°C in M-199 
(without Phenol red) with endotoxm (LPS lipopolysaccharide from 
E cob strain: 055:B5) (Sigma, France). IL-l/I or TNF-a (Tebu, 
France) in the absence or presence of the indicated concentrations of 
IL-4 (Tebu, France) or IL-13 which was cloned. produced and purified 
as described [8]. The medium was removed and the wells were washed 
twice with 1 ml of phosphate buffered saline (PBS) and incubated for 
45 mm at 37°C with 250 ~1 of M-199 contammg PPSB (0.44 U/ml 
FVII) (Intertransfusion, France) and 100 pg./ml of substrate S2222 
(Kabi, Sweden). The optical density (OD) was measured at 405 nm. 
The TF activity was obtained from a standard curve (log [dOD,,,,/min] 
vs. log [U/ml]) using serial dilutions of rabbit bram thromboplastm in 
M-199 assayed as described above. Undiluted thromboplastm was 
arbitrarily assigned a value of 1 U/ml. The TF activity was normalized 
to the cell counts from the same well and expressed as PUnits of 
TF/lO’ cells. 
2 3. Detern7mation qf tlwumhomudulm activrt? 
Confluent endothehal cells were incubated with IL-4 or IL-13 m the 
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presence of LPS (1 @ml), IL-ID (10 ng/ml) or TNF-a (1 @ml). After 
24 h, cells were washed once with M 199. Purified human protein C 
(PC) (CTS, France) (60 mM) and purified human a-thrombin (CTS. 
France) (1 NIH U/ml) were incubated in 140 ~1 of M 199 containing 
0.3% human serum albumin for 60 minutes at 37°C. Free thrombin 
was neutralized by an excess of recombinant hirudin (Sanofi Recher- 
the, France) (20 ATU/ml) and the PC activity was determined by 
adding 100 ~1 of 0.2 mM S 2366. After 30 min. OD,,, nm was meas- 
ured. 
3. RESULTS AND DISCUSSION 
3.1. Effect of LPS, IL-la and TNF-a on TF and TM 
expression 
Unstimulated cells were devoid of TF activity, i.e. 
demonstrated the same insignificant hydrolysis of 
S2222 in the test but the addition of LPS, IL-l/? or 
TNF-a to adherent endothelial cells and monocytes re- 
sulted in a dose-dependent expression of TF on the cell 
surface (Fig. lA,B). The various inflammatory media- 
tors showed different dose-responses for TF induction 
on the two cell types. LPS was the most potent stimula- 
tor on ABAE whereas IL-la was more potent on mon- 
ocytes. These compounds also induced the down-regu- 
lation of TM expression at the surface of the endothelial 
cells (Fig. 1C). These results confirm previous observa- 
tions [5-7,12-141 and show that, on the surface of cul- 
tured endothelial cells, a procoagulant entity (TF) or an 
anti-coagulant one (TM) is simultaneously regulated by 
stimuli such as IL-lp or TNF-a which are susceptible 
to be secreted in pathological situations leading to 
thrombosis. 
3.2. Effect of IL-4 and IL-13 on pyrogen-induced TF and 
TM expression 
As shown in Fig. 2A, IL-4 and IL-13 counteracted in 
a dose-dependent manner IL-lj?-, TNFa- and LPS-in- 
duced TF induction in ABAE. The IC50 values (con- 
centrations which inhibited 50% of the pyrogen-induced 
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Fig. 1. Effect of LPS, IL-lb and TNF-a on TF and TM expression. 
ABAE (AC) and human monocytes (B) were Incubated with increas- 
ing concentrations of LPS (0). IL-l/3 (w) or TNF-a (A). TF (A,B) and 
TM (C) expression was quantified as described m Section 2. Results 
are expressed as mean k SD. (n = 6). 
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Fig. 2. Effect of IL-4 and IL-13 on LPS, IL-l/? or TNFa-induced expression of TF in ABAE and monocytes. Increasing concentrattons of IL-4 
(full symbols) and IL-13 (empty symbols) were incubated with ABAE (A) or human monocytes (B) in the presence of LPS (o,:_I), IL-l/l (W.0) or 
TNF-a (A& at the indicated concentrations. TF expresston was determmed as described in Section 2. Results are expressed as % inhibition of 
the control response (n = 6). 
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Fig. 3. Effect of IL-4 and IL-I 3 on pyrogen-induced TM down-regu- 
latton in ABAE. Confluent ABAE were incubated with LPS (1 ng/ml). 
IL-l/I (10 @ml) or TNF-a (1 ng/ml) in the presence of the vehicle 
(empty bars), IL-4 (shaded bars) or IL-13 (full bars) (10 @ml). TM 
expresston was determmed as described under Sectton 2 and expressed 
as a percent of the control response observed in the absence of pyrogen 
(n = 6). 
TF expression) with regard to the effect of all inflamma- 
tory mediators were between 0.05 and 0.5 ng/ml. In 
human monocytes (Fig. 2B). IL-4 and IL-l 3 strongly 
reduced IL-lb-induced TF expression with IC50 values 
of 0.4 and 1.3 ng/ml, respectively. With regard to the 
procoagulant effect of TNF-ol, both IL-4 and IL-13 
remained ineffective whereas they slightly inhibited the 
procoagulant effect of LPS. 
In experiments performed in parallel, IL-4 and IL-13 
reduced LPS-. IL-l/?- or TNF-a-induced TM down- 
regulation in ABAE (Fig. 3). Such observations have 
already been described for IL-4 [6]. The concentrations 
of IL-4 and IL-13 (10 rig/ml) which counteracted LPS-. 
IL-l/?- or TNF-a-induced TM down-regulation were in 
the same range as those shown to alter pyrogen-induced 
TF expression. 
Although pyrogen-induced pro-hemostatic changes 
in the endothelial cell surface have been known for sev- 
eral years. a substance that effectively counteracts these 
effects has not so far been described. Recently, IL-4, a 
product of activated T-cells, was shown to exert anti- 
inflammatory effects on human endothelial cells and 
monocytes [15-171 and to neutralize the pyrogen-in- 
duced down-regulation of thrombomodulin activity [6]. 
We further provided evidence that IL-4 effectively 
counteracted the procoagulant process resulting from 
the interaction of inflammatory mediators with endo- 
thelial cells and monocytes [7]. 
We now show that IL-13, exhibits a comparable abil- 
ity to reduce pyrogen-induced procoagulant activity in 
endothelial cells and monocytes but further work is now 
needed to determine if IL-13 is able to modulate the 
prothrombotic and proinflammatory properties of such 
compounds. The similar action of IL-13 and IL-4 on the 
procoagulant activity of monocytes and endothelial 
cells resembles their common inhibition of inflamma- 
tory cytokine synthesis by monocytes [S]. The activity 
of IL-13 on endothelial cells therefore adds another cell 
type to the wide range of target cells identified for this 
novel pleiotypic lymphokine. 
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